1 / 6

HBV related complications in HIV positive patients during HAART therapy

Abstract no. WEPDB204. HBV related complications in HIV positive patients during HAART therapy. Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona Diaconu** *Ovidius University, Faculty of Medicine, ** Clinical Infectious Diseases Hospital, Constanta, ROMANIA .

fairly
Download Presentation

HBV related complications in HIV positive patients during HAART therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abstract no. WEPDB204 HBV related complications inHIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona Diaconu** *Ovidius University, Faculty of Medicine, ** Clinical Infectious Diseases Hospital, Constanta, ROMANIA

  2. The natural history of HBV is known to be complicated by HIV coinfection, with a higher rate of chronic hepatitis, greater levels of HBV replication and lower incidences of spontaneous loss of HBeAg or HBsAg. We evaluated the long term evolution of liver disease among HIV/HBV coinfected patients receiving HAART. Background Methods • Prospective, observational cohort study of 72 patients with HIV/HBV coinfection, without signs of liver disease in the begining of the study period. • The patients were treated with HAART, during a period of five years. • Clinical and biological data were collected every 3 months, immunological and virological data every six months, ultrasound every year. • In the last year we performed Fibroscan in every patient. • Determination of HBV drug resistance was performed in cases with detectable serum HBV-DNA level (HBV-DNA < 55 UI/mL).

  3. Patients characteristics

  4. Results • After five years of follow-up, advanced liver disease was diagnosed in 8/72 patients: • 5 liver cirrhosis • 2 hepatocellular carcinoma • 1 fulminant hepatitis • All these patients had: • high level of serum HBV-DNA • lamivudine resistance (M204V, M204I, L180M, L180I) • undetectable serum level of HIV • Five of these patients died • The rest of 64 patients had no signs of active liver disease: • normal or less than 2 x ULN level of ALT, • F0-F1 according to Fibroscan • In these patients, serum HBV-DNA was detectable in another 14 cases • Lamivudine resistance was founded in 10 cases Detectable HBV-DNA

  5. Conclusion • In HIV/HBV coinfected patients treated with HAART, LAM resistance is less frequent (25%) than in immunocompetent patients (higher than 60%*), but when occurred, was associated with: • an accelerated course of liver disease • faster progression to cirrhosis • liver insufficiency • HCC • Appropriate monitoring of chronic viral hepatitis B in HIV positive patients include the recognition of LAM resistence in every case of detectable HBV-DNA level. * Fischer KP et al. Drug Resist Updat.2001, Pallier C et al. J Virol 2006

More Related